Molecular dermatology research and development company, DermaGenoma, Inc. today announced that the PsoriasisDX Genetic Test for Psoriatic Arthritis (PsA) is now available as a CE Marked product under the European In Vitro Diagnostic Directive.
CE Marking is required for certain product groups to indicate conformity with the essential requirements set out in European Directives. The PsoriasisDX Genetic Test for Psoriatic Arthritis complies with the essential requirements of the European IVD Directive.
Already available in the United States, the PsoriasisDX Genetic Test helps identify those at high risk for developing Psoriatic Arthritis before they experience arthritic symptoms, providing the opportunity to lessen joint damage through early medical intervention.
The test is available through physician’s offices nationwide, and are administered using simple cheek swabs.
(Source: Press Release)